Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 44

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2018

Summary

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide.

Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH) and Parkinson's Disease.

Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

- The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects

- The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
Antag Therapeutics ApS
Carmot Therapeutics Inc
Eli Lilly and Co
Hanmi Pharmaceuticals Co Ltd
Longevity Biotech Inc
Novo Nordisk AS
Sanofi
Zealand Pharma AS
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3298176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-9423 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-438335 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441255 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GLP1 and GIP Receptors for Non Alcoholic Steatohepatitis, Obesity and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPDI-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPI-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting
Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Antag Therapeutics ApS, H2 2018
Pipeline by Carmot Therapeutics Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Pipeline by Longevity Biotech Inc, H2 2018
Pipeline by Novo Nordisk AS, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by Zealand Pharma AS, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Effervescent Tablet Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 116
    Effervescent tablets are designed to break in contact with liquid such as water or juice, often causing the tablet to dissolve into a solution. In 2017, the global Effervescent Tablet market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Effervescent Tablet market based on company, product type, application and key regions. This report stud......
  • Global Rivanol Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 117
    Rivanol is for external use sterilization preservative, the gram positive bacteria and a few gram-negative bacteria have strong exterminate action, to cocci especially streptococcus antibacterial effect strong. It is used for all kinds of wounds, seepage, erosion of infectious skin disease and wound flushing. In 2017, the global Rivanol market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, ......
  • Global Pregnant Vitamin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 115
    For pregnant women, vitamin supplements are needed during pregnancy to ensure adequate nutrition for the fetus. Vitamins are essential not only for pregnant women, but also for the development of babies. In 2017, the global Pregnant Vitamin market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Pregnant Vitamin market based on company, product type, applic......
  • Global Children Calcium supplement Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 119
    Calcium is the essential building block of bones and teeth, Children Calcium Tablet can provide daily calcium volume to children. In 2017, the global Children Calcium supplement market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Children Calcium supplement market based on company, product type, application and key regions. This report st......
  • Global G-CSF and G-CSF Biosimilars Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 115
    G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation. In 2017, the global G-CSF and G-CSF Biosimilars market size was xx million US$ and is forecast to xx m......
  • Global Animal Health Products Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 112
    Animal Health Products include some products vaccines, pharmaceuticals, feed additivies and others. In 2017, the global Animal Health Products market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Animal Health Products market based on company, product type, application and key regions. This report studies the global market size of Animal H......
  • Global Human Endostatin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 114
    This report studies the global market size of Human Endostatin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Endostatin in these regions. This research report categorizes the global Human Endostatin market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, o......
  • Global Poliomyelitis Vaccine in Dragee Candy Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 113
    This report studies the global market size of Poliomyelitis Vaccine in Dragee Candy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Poliomyelitis Vaccine in Dragee Candy in these regions. This research report categorizes the global Poliomyelitis Vaccine in Dragee Candy market by players/brands, region, type and application. This report also studies the global market status, competition landsca......
  • Global Interleukin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 113
    This report studies the global market size of Interleukin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Interleukin in these regions. This research report categorizes the global Interleukin market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs